Survey response rates were 6% for group 1, 15% for group 2, and 15% for group 3. Sensitivity analysis determined that respondents and nonrespondents had similar age and sex distributions, suggesting that respondents were representative of the study sample. In response to specific clinical scenarios, more than 95% of respondents from each group selected a topical or oral antiviral agent for treating HSV epithelial keratitis (Table). For HSV stromal keratitis, only 54% from group 1, as compared with 74% and 82% from groups 2 and 3, respectively, chose to combine a topical corticosteroid agent and an antiviral agent as treatment (P < .001). When prompted with a patient with repeated visually significant recurrences of HSV stromal keratitis, 51%, 60%, and 62% of groups 1, 2, and 3, respectively, chose to use an oral antiviral agent to prevent future episodes (P < .001).